---
figid: PMC8430485__cancers-13-04345-g002
figtitle: 'Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic
  Review of Clinical Outcomes'
organisms:
- NA
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC8430485
filename: cancers-13-04345-g002.jpg
figlink: /pmc/articles/PMC8430485/figure/cancers-13-04345-f002/
number: F2
caption: 'Molecular mechanisms of targeted drugs approved by the Food and Drug Administration
  for the treatment of metastatic colorectal cancer. (1) Anti-EGFR (epidermal growth
  factor receptor) monoclonal antibodies (mAbs) cetuximab and panitumumab; (2) encorafenib,
  an inhibitor of the Raf protein as part of the MAPK/ERK signaling pathway; (3) VEGF-A
  (vascular endothelial growth factor-A) inhibitors aflibercept and bevacizumab; (4)
  VEGF receptor inhibitors regorafenib and ramucirumab; (5) anti-PD-1 (programmed
  cell death-1) mAbs nivolumab and pembrolizumab and anti-PD-L1 (programmed cell death
  ligand 1) mAbs atezolizumab, durvalumab and avelumab; (6) anti-CTLA-4 (cytotoxic
  T lymphocyte-associated antigen-4) mAb ipilimumab. Current targeted therapies inhibit
  three major processes crucial for cancer growth: unrestricted proliferation, neo-angiogenesis
  and suppression of T cell immune responses.'
papertitle: 'Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic
  Review of Clinical Outcomes.'
reftext: Dmitrii Shek, et al. Cancers (Basel). 2021 Sep;13(17):4345.
year: '2021'
doi: 10.3390/cancers13174345
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: colorectal cancer | pembrolizumab | atezolizumab | nivolumab | ipilimumab
  | targeted therapy | immune-checkpoint inhibitors
automl_pathway: 0.9578155
figid_alias: PMC8430485__F2
figtype: Figure
redirect_from: /figures/PMC8430485__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8430485__cancers-13-04345-g002.html
  '@type': Dataset
  description: 'Molecular mechanisms of targeted drugs approved by the Food and Drug
    Administration for the treatment of metastatic colorectal cancer. (1) Anti-EGFR
    (epidermal growth factor receptor) monoclonal antibodies (mAbs) cetuximab and
    panitumumab; (2) encorafenib, an inhibitor of the Raf protein as part of the MAPK/ERK
    signaling pathway; (3) VEGF-A (vascular endothelial growth factor-A) inhibitors
    aflibercept and bevacizumab; (4) VEGF receptor inhibitors regorafenib and ramucirumab;
    (5) anti-PD-1 (programmed cell death-1) mAbs nivolumab and pembrolizumab and anti-PD-L1
    (programmed cell death ligand 1) mAbs atezolizumab, durvalumab and avelumab; (6)
    anti-CTLA-4 (cytotoxic T lymphocyte-associated antigen-4) mAb ipilimumab. Current
    targeted therapies inhibit three major processes crucial for cancer growth: unrestricted
    proliferation, neo-angiogenesis and suppression of T cell immune responses.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGF
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EGFR
  - EPHB2
  - MAPK1
  - MAPK3
  - KDR
  - FLT1
  - FLT4
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - VEGFA
  - CD4
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CD274
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - HLA-C
  - CTLA4
  - CD80
  - Egfr
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - Pvr
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Mtor
  - Tor
  - Pvf1
  - Tcr
  - Mhc
  - zip
---
